Catalent Invests Millions to Create European Clinical Manufacturing Center of Excellence

July 21, 2020

Catalent has unveiled investment plans to create a European center of excellence for clinical biologics formulation development and drug product fill/finish services.

AstraZeneca/Oxford Vaccine Shows Antibody and T-cell Responses

July 20, 2020

A strong immune response by patients receiving two doses of AZD1222 vaccine suggests a possible dosing strategy for COVID-19 vaccine.

VAR2 Pharmaceuticals Wins MilliporeSigma’s Advance Biotech Grant

July 08, 2020

VAR2 Pharmaceuticals has been selected for its development of a drug-conjugated malaria protein that potentially selectively binds to most human tumor types.

Sartorius Stedim Biotech Launches Consultancy Services for Viral Clearance Validation

June 30, 2020

The company now offers its CONFIDENCE virus clearance services to support validation of viral clearance processes.

FDA Revokes EUA for Hydroxychloroquine

June 15, 2020

Citing clinical trial data that hydroxychloroquine did not show benefits for COVID-19 patients, FDA removes emergency use authorization for the drug as a treatment for the novel coronavirus.

Novavax Secures $60 Million in Government Funds

June 08, 2020

Novavax announces DoD contract to produce 10 million doses of COVID-19 vaccine candidate.

Ajinomoto Bio-Pharma Services, Humanigen in Manufacturing Agreement for COVID-19 Biologic

June 01, 2020

The companies have entered into a manufacturing agreement for the fill finish supply of lenzilumab for the potential treatment of COVID-19.

Novavax Acquires Praha Vaccines, Expands Large-Scale Vaccine Manufacturing Capacity

June 01, 2020

The acquisition gives Novovax an annual operating capacity of more that one billion doses of COVID-19 vaccine antigen.

Are We All In This Together?

June 01, 2020

Achieving herd immunity will require testing, data, a vaccine, and public support.

The Role of Incubators in Cell and Gene Therapy Development

June 01, 2020

Working with incubators can provide cell and gene therapy developers with more opportunities.